3White P, Thornton H, Pinnock H, et al. Overtreatment of COPD with inhaled eorticosteroids-implications for safety and costs : cross-sectional observational study [ J ]. PLoS One, 2013 (10) :75221.
4Sundblad BM, Jansson SA, Nystrom L, et al. Chronic ob- structive pulmonary disease (COPD) during the two last years of life - a retrospective study of decedents [ J ]. PLoS One, 2013(12) :84110.
5Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review[ J ]. Respir Res, 2011 (12) :45.
6Pank N, Klimesova S, Kara J, et al. The relevance of mo- nitoring of antibodies against the polycyclic aromatic hydro- carbon (PAH) and PAI-I-DNA adducts in serum in rela-tion to lung cancer and chronic obstructive pulmonary dis- ease (COPD) [ J ]. Neoplasma, 2013 (2) : 182 - 187.
7Sahin ZA, Sahin M. The view of patients with Choronic Obstructive Pulmonary Disease (COPD) on Complementa- ry and Ahernative Medicine (CAM) in Eastern Turkey [ J ]. African journal of traditional, complementary, and alternative medicines : AJTCAM/African Networks on Eth- nomedicines, 2013(4) :116 - 121.
8Hoiseth AD, Omland T, Karlsson BD, et al. Standardized evaluation of lung congestion during COPD exacerbation better identifies patients at risk of dying [ J ]. Int J Chron Obstruct Pulmon Dis, 2013 (8) :621 - 629.
9Wells JM, Dransfield MT. Pathophysiology and clinical im- plications of pulmonary arterial enlargement in COPD [ J ]. Int J Chron Obstruct Pulmon Dis, 2013(8):509 -521.
10Bhatt SP, Peterson MW, Wilson JS, et al. Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial [ J ]. Int J Chron Obstruct Pulmon Dis, 2013 (8) :581 - 589.
